Massachusetts compromises on weaker Medicaid drug price disclosure

Responding to a biopharma industry lobbying campaign, the Massachusetts legislature has dialed back drug price and cost disclosure requirements. The requirements are part of provisions in the state budget that create a new Medicaid supplemental rebate for high-priced drugs.